Anna Koroleva

1.3k total citations · 3 hit papers
12 papers, 863 citations indexed

About

Anna Koroleva is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Molecular Biology. According to data from OpenAlex, Anna Koroleva has authored 12 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Pharmacology and 7 papers in Molecular Biology. Recurrent topics in Anna Koroleva's work include Diabetes Treatment and Management (9 papers), Metabolism, Diabetes, and Cancer (7 papers) and Pharmacology and Obesity Treatment (6 papers). Anna Koroleva is often cited by papers focused on Diabetes Treatment and Management (9 papers), Metabolism, Diabetes, and Cancer (7 papers) and Pharmacology and Obesity Treatment (6 papers). Anna Koroleva collaborates with scholars based in Denmark, United States and Ireland. Anna Koroleva's co-authors include Signe Olrik Rytter Wallenstein, Thomas A. Wadden, Ildiko Lingvay, Domenica Rubino, W. Timothy Garvey, Juan P. Frías, Patrick M. O’Neil, Melanie J. Davies, Timothy S. Bailey and Liana K. Billings and has published in prestigious journals such as New England Journal of Medicine, JAMA and Diabetes.

In The Last Decade

Anna Koroleva

11 papers receiving 845 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

2021 646 citations Thomas A. Wadden, Timothy S. Bailey et al. JAMA profile →
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

2024 119 citations Henning Bliddal, Harold Bays et al. New England Journal of Medicine profile →
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial

2024 59 citations Yiming Mu, Freddy G. Eliaschewitz et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Koroleva Denmark	6	617	498	254	249	151	12	863
Signe Olrik Rytter Wallenstein United States	5	537 0.9×	428 0.9×	214 0.8×	245 1.0×	130 0.9×	9	717
Arash Pakseresht Denmark	7	707 1.1×	499 1.0×	257 1.0×	310 1.2×	233 1.5×	12	975
Altynai Satylganova Denmark	9	471 0.8×	342 0.7×	246 1.0×	199 0.8×	153 1.0×	12	780
Louise Færch Denmark	7	720 1.2×	414 0.8×	239 0.9×	279 1.1×	240 1.6×	16	930
Trine Vang Skjøth Denmark	12	1.1k 1.8×	614 1.2×	304 1.2×	384 1.5×	344 2.3×	23	1.3k
V. Woo Canada	2	453 0.7×	421 0.8×	245 1.0×	137 0.6×	110 0.7×	3	612
Simon Birk Kjær Jensen Denmark	9	336 0.5×	248 0.5×	270 1.1×	121 0.5×	102 0.7×	15	666
Camilla Jensen Denmark	8	496 0.8×	377 0.8×	343 1.4×	191 0.8×	106 0.7×	16	828
Wissam Ghusn United States	13	280 0.5×	142 0.3×	205 0.8×	98 0.4×	239 1.6×	59	565
Deborah B. Horn United States	13	241 0.4×	151 0.3×	210 0.8×	101 0.4×	183 1.2×	30	582

Countries citing papers authored by Anna Koroleva

Since Specialization

Citations

This map shows the geographic impact of Anna Koroleva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Koroleva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Koroleva more than expected).

Fields of papers citing papers by Anna Koroleva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Koroleva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Koroleva. The network helps show where Anna Koroleva may publish in the future.

Co-authorship network of co-authors of Anna Koroleva

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Koroleva. A scholar is included among the top collaborators of Anna Koroleva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Koroleva. Anna Koroleva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Bliddal, Henning, Harold Bays, Sébastien Czernichow, et al.. (2024). Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the STEP 9 randomised clinical trial. Osteoarthritis and Cartilage. 32(6). 745–746. 14 indexed citations

Bliddal, Henning, Harold Bays, Sébastien Czernichow, et al.. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 391(17). 1573–1583. 119 indexed citations breakdown →

Mu, Yiming, Freddy G. Eliaschewitz, Morten Hansen, et al.. (2024). Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. The Lancet Diabetes & Endocrinology. 12(3). 184–195. 59 indexed citations breakdown →

Roux, Carel W. le, et al.. (2024). Anti‐obesity treatment preferences of healthcare providers and people living with obesity: A survey‐based study. Clinical Obesity. 15(1). e12704–e12704. 3 indexed citations

Kushner, Robert F., W. Timothy Garvey, Dan Hesse, et al.. (2022). Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1). Indian Journal of Endocrinology and Metabolism. 26(Suppl 1). S9–S9. 1 indexed citations

Koroleva, Anna, et al.. (2022). The role of IL-33 and IL-1β in the development of persistent allergic rhinitis in overweight/obese children. Russian Journal of Allergy. 19(4). 472–482.

Wadden, Thomas A., Timothy S. Bailey, Liana K. Billings, et al.. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 325(14). 1403–1403. 646 indexed citations breakdown →

Kushner, Robert F., W. Timothy Garvey, Dan Hesse, et al.. (2021). Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1). Journal of the Endocrine Society. 5(Supplement_1). A24–A24. 9 indexed citations

Wadden, Thomas A., Timothy S. Bailey, Liana K. Billings, et al.. (2021). 4 Semaglutide 2.4 mg and Intensive Behavioral Therapy in Subjects With Overweight or Obesity (STEP 3). 2 indexed citations

10.

Garvey, W. Timothy, Dan Hesse, Anna Koroleva, et al.. (2021). Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History. Endocrine Practice. 27(6). S80–S81. 1 indexed citations

11.

Mosenzon, Ofri, W. Timothy Garvey, Dan Hesse, et al.. (2021). Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4). Journal of the Endocrine Society. 5(Supplement_1). A7–A7. 5 indexed citations

12.

Lingvay, Ildiko, Louise Færch, Anna Koroleva, et al.. (2021). 83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2). Diabetes. 70(Supplement_1). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact